Pharmafile Logo
Pharmafocus logo
Advanced Search

Moderna agrees first acquisition for $85m

January 6, 2023
Sales and Marketing

After a pivotal few years, Moderna has agreed its first acquisition, worth $85m, which will allow the company access to …

News

BioNTech and UK Government announce strategic partnership to provide mRNA cancer immunotherapies

January 6, 2023
Medical Communications

German biotech company BioNTech and the UK Government have signed a Memorandum of Understanding (MoU) which will accelerate clinical trials …

News

Withings announces hands-free connected in-home urine lab

January 6, 2023
Medical Communications

Connected health firm Withings has unveiled its new in-home biomarker analysis platform U-Scan. It is hoped the device will utilise …

News

Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs

January 5, 2023
Medical Communications

AMSTERDAM, THE NETHERLANDS, 5 January 2023 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for …

News
Press release

Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combination with KEYTRUDA® (pembrolizumab) in a Phase 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer

January 5, 2023
Business Services

BASEL, Switzerland – 5th January 2023 – Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, today announced …

News
Press release

Lidia Oostvogels

January 5, 2023
Business Services

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Appointment

iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program

January 5, 2023
Business Services

Geneva, Switzerland and Amsterdam, The Netherlands, 5 January – iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that …

News
Press release

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

January 5, 2023
Business Services

Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) …

News
Press release

Sosei Heptares Notes its Partner Tempero Bio has Received FDA Clearance to Advance Clinical Development of TMP-301 for Treatment of Alcohol and Substance Use Disorders

January 5, 2023
Business Services

Tokyo, Japan and Cambridge, UK, 5 January 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in …

News
Press release

FDA accepts application for nirsevimab as first protective option for RSV in infants

January 5, 2023
Medical Communications

The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease …

News

Island Pharmaceuticals to begin phase 2 trial for dengue prevention and treatment drug

January 5, 2023
Research and Development

It is possible that Island Pharmaceuticals could begin its phase 2a PEACH clinical trial as soon as January 2023. The …

News

Belharra Therapeutics and Genentech join forces for small molecule medicine development

January 5, 2023
Research and Development

US-based biotech companies Belharra Therapeutics and Genentech have announced a multi-year partnership to lead the discovery and development of small …

News

Biogen and Alcyone Therapeutics enter partnership to develop ThecaFlex DRx system for ASO therapies

January 5, 2023
Research and Development

US-based Biogen and Alcyone Therapeutics have entered into a license and collaboration agreement to develop Alcyone’s ThecaFlex DRx™ System.   …

News

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

January 4, 2023
Business Services

Amsterdam and San Francisco / Houston / Singapore, 4 January 2023 — Synaffix B.V.

News
Press release

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

January 4, 2023
Business Services

Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to …

News
Press release

Dr Samson Fung

January 4, 2023
Business Services

Molecure Appoints Dr. Samson Fung, Chief Medical Officer to its Management Board as it Continues to Focus on Successfully Progressing …

Appointment

Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders

January 4, 2023
Business Services

London, UK – 4 January 2023. Actimed Therapeutics Ltd, a UK based clinical stage specialty pharmaceutical company focused on bringing …

News
Press release

FDA expands access to abortion pills

January 4, 2023
Medical Communications

Following new rules from the FDA under the Biden administration, patients can now obtain the abortion pill mifepristone from retail …

News

Novartis pays $245m to settle Exforge generic pay-for-delay lawsuit

January 4, 2023
Medical Communications

Swiss pharma company Novartis will settle a classic generic pay-for-delay legal battle with direct purchasers, indirect purchasers and retailers regarding …

News

FDA grants Breakthrough Device Designation for Burning Rock’s multi-cancer detecting test

January 4, 2023
Medical Communications

Burning Rock, a Chinese biotech company which focuses on the applications of next-generation sequencing (NGS) technology in the field of …

News
The Gateway to Local Adoption Series

Latest content

Five Facts about spinal muscular atrophy

January 28, 2026

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026

Everdrone appoints David Borkmann as Senior Medical Advisor

January 28, 2026

MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance

January 27, 2026

Crystalys Therapeutics appoints Justin Thacker as Chief Financial Officer

January 27, 2026